Back to news
Poster
Wed. 29 June

In vivo PK/PD profile of Compound A

Share on

In vivo PK/PD profile of Compound A,
a brain penetrant, orally available potent and selective LRRK2 inhibitor, in rodent and non-rodent species

Authors

Arnaud François, Pascal Grondin, Guillaume Das Dores, Aurore Sors, Anne-Pascale Luzy, Cédric Vinson, Yann Lamotte, Petra Blom, Arnaud Le Tiran, Laurence Danober, Johannes Krupp, Jan Hoflack and Nicolas Ancellin

Objectives

Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are the most common genetic cause of Parkinson’s disease, leading to the development of LRRK2 inhibitors as potential therapeutic approach. Among them, Compound A has recently been selected as a potent, selective and brain-penetrant LRRK2 inhibitor. In order to confirm its in vivo target engagement and equipotency on wild type and G2019S LRRK2 mutants, several Pharmacokinetic/Pharmacodynamic (PK/PD) studies were performed in rodent and non-rodent species.

 

Prepared in collaboration with Servier

 

Please see the accompanying poster for the In vitro pharmacological profile of compound A

Read the others news

Financial
News
Press Release
Uncategorized
Tue. 19 September
Press Release
Uncategorized
Tue. 30 May
Financial
News
Press Release
Thu. 13 April
and provides an update on its clinical developments

Subscribe to the OPM newsletter

Subscribe to the newsletter to not miss any news!